The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeuti...

Full description

Saved in:
Bibliographic Details
Published inSeminars in hematology Vol. 58; no. 1; p. 56
Main Authors Gonzalez-Lugo, Jesus D, Chakraborty, Samarpana, Verma, Amit, Shastri, Aditi
Format Journal Article
LanguageEnglish
Published United States 01.01.2021
Subjects
Epigenesis, Genetic
Epigenomics
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Mutation
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - genetics
Online AccessGet more information

Cover

More Information
Summary:Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments.
ISSN:1532-8686
DOI:10.1053/j.seminhematol.2020.12.003